Introduction
Hemorrhagic cystitis (HC) is often a serious complication of renal and hematopoietic stem cell transplants (HSCT), with the potential to cause significant morbidity. [1] [2] [3] It occurs in up to 70% of HSCT recipients and is associated with prolonged hospitalization. 4, 5 Early bleeding (occurring 24-72 hours after transplant) is usually ascribed to toxic effects of drugs, while late occurring cystitis is multifactorial. [4] [5] [6] [7] [8] Reported predisposing factors include allogeneic transplant, advanced age at transplantation, possibly graftversus-host disease (GVHD), thrombocytopenia, coagulopathy and viral infections (polyoma BK virus, cytomegalovirus and adenovirus). Non-chemotherapy induced HC is usually documented later after HSCT (more than 2 weeks in the allogeneic setting). [9] [10] [11] [12] [13] Polyomavirus hominis 1 (genus Polyomaviridae), the BK virus, is a non encapsulated DNA virus that is highly prevalent in healthy adults with up to 90% seropositivity. The transmission is believed to occur via the respiratory tract, especially during earlychildhood years. Infection is usually asymptomatic or may be associated with fever and mild upper respiratory symptoms. 10, 11, 14 After first infection, polyomavirus can be latent in the kidneys, urothelium, and other organs, and may reactivate during immunosuppression. BK virus infection has been connected with development of HC after allogeneic transplant, but most studies detected the virus at the time of bleeding, therefore not allowing estimation of the risk imposed by asymptomatic infection. 7, 15 We have shown that HC is more likely to occur in unrelated than in related-donor HSCT 21 , and in this analysis we focused on patients receiving unrelated or mismatched haploidentical related HSCT. Here we postulated that a positive BK viruria documented by PCR prior to transplant would increase the risk of HC in recipients of unrelated or 4 haploidentical transplants. Because of poorer immune reconstitution, we also hypothesized that recipients of cord blood and haploidentical transplants would have a higher incidence of HC than recipients of unrelated donor transplants, and prospectively investigated these hypotheses in a cohort of such patients transplanted in our institution.
Materials and Methods

Patient and treatment characteristics
The study cohort includes 80% of all adult patients that underwent allogeneic HSCT using an unrelated, haploidentical related, or unrelated cord blood donor at The samples, those that died early (within the first 30 days after HSCT) or that were undergoing a second transplant. Data regarding treatment outcomes were prospectively collected in the department database. Patients were monitored for signs and symptoms of HC on a daily basis during the initial admission for HSCT, then twice weekly after discharge until approximately 100 days after transplant. The retrospective data review was approved by the institutional review board at UTMDACC.
Patient and treatment characteristics are presented in Table 1 . Most patients received unrelated bone marrow or peripheral blood stem cell transplants (85%), after a myeloablative or reduced intensity conditioning regimen in 52% and 48% of the cases, respectively. GVHD prophylaxis consisted of tacrolimus in combination to minimethotrexate 5 mg/m 2 on days +1, +3, +6 and +11 (n=178), or to mycophenolate mophetyl (n=23), or CD34 selection/T cell depletion in haploidentical transplants (n=8).
Anti-thymocyte globulin was part of the preparative regimen in all transplants with the exception of Campath-containing combinations. Median time to neutrophil and platelet engraftment was 14 days (range, 1-51), and 20 days (range, 9-64), respectively.
Cumulative incidence of grade II-IV and III-IV acute GVHD was 33% and 12%, respectively. Patients developing grade II-IV acute GVHD were initially treated with 2 mg/Kg of methylprednisolone. For the purposes of this analysis, only grade II-IV acute GVHD cases were included.
Definitions
Considering that HC occurred as frequently in all quartiles of polyoma viruria, BK virus PCR was considered positive if any number of viral copies were detected. HC occurring more than 1 week after transplant was defined as "late-onset". Cystitis was defined by presence of dysuria, pain, increased frequency and/or other urinary tract symptoms, and by the presence of hematuria. HC was graded as following: grade 0 = none; grade I = microscopic hematuria with urinary symptoms; grade II = macroscopic hematuria; grade III = macroscopic hematuria with clots, and grade IV = macroscopic hematuria with intervention for clot evacuation and/or urinary retention. 2, 6, 12 Patients with HC and clots were treated with continuous bladder irrigation, and percutaneous nephrostomy was used if persistent hydronephrosis was documented. 
Urine Cytology
We also performed urine cytology in the same samples, searching for cytologic changes compatible with polyoma virus infection. 23 Each urine specimen was processed for cytologic evaluation by centrifugation for 10 minutes at 300 rcf. The sample was resuspended after stepwise addition of 2-5 ml. of glacial acetic acid with vortex, immediately followed by 2-5 ml. of normal saline with vortex. The sample was then centrifuged for 5 minutes at 300 rcf. After removal of supernatant, the sediment was pulled into a glass Pasteur pipette and examined for clarity. Cytospin slides were prepared by centrifugation for 5 minutes at 80 rcf and immediately fixed in 95% alcohol and stained by the Papanicolaou method. Polyomavirus cytopathic effect was identified in samples containing cells exhibiting marked nuclear enlargement with ground glass chromatin (viral inclusion; "decoy cell") occupying most of the nucleus and/or lace-like clumped chromatin (empty post-inclusion).
Statistical methods
The one-year cumulative incidence of HC was estimated considering death without hemorrhage as a competing event. Risk factors for the development of HC were evaluated on univariate and multivariate analysis using Cox regression model. The following variables were included: donor type (unrelated, haploidentical and cord blood), conditioning regimen intensity, BK virus PCR status prior to, and on day 30 after HSCT, use of cyclophosphamide, stem cell source, age, engraftment, and acute GVHD. Since median time to HC was less than 60 days, day 60 viruria was not used in the model.
Landmark analysis was used to assess the correlation between BK virus PCR status on transplant day 30 and subsequent rate of HC development. Statistical significance was defined at the 0.05 level. Statistical analysis was performed using STATA 9.0. 
Results
Hemorrhagic cystitis
BK viruria and hemorrhagic cystitis
The mean number of viral copies pre-HSCT among those with positive PCR was 1.9 x 10 7 copies/mL (range, 300 -2 x 10 8 copies/mL). Viral load did not have a direct correlation with development of HC. We actually saw HC among patients with very low levels of viruria, and the proportion of patients with HC was similar among patients in the lower and higher quartiles, as follows: 25% quartile, 2,100 copies/mL and 17% rate of HC; 50% quartile, 12,000 copies/mL and 12% of HC; 75% quartile, 140,000 copies/mL and HC in 17%; and 95% quartile, 2 x 10 8 copies/mL, HC rate of 17%.
Among patients who were BK virus positive prior to transplant (n=96), the median log BK viral load pre HSCT was not significantly different in patients that subsequently bled (n=15/96; median of 9.5 copies/mL, range 5-19) versus those that did not develop HC (n=81/96; median of 9.4 copies/mL, range 5.3-19, p=0.8).
Mean polyoma viruria was 9.7 x 10 7 copies/mL (range, 300 -2 x 10 8 copies/mL, n=105) and 7.7 x 10 7 copies/mL (range, 200 -2 x 10 8 viral copies/mL; n=101), respectively 30 and 60 days after HSCT. There was a statistically significant increase in mean viruria from pre HSCT when compared to both time points after transplant (P=0.0002 and P=0.002, respectively). We repeated the PCR at the time of diagnosis of HC in 11 cases.
Viral load increased in 8 cases and remained the same in 3, when compared to pre HSCT levels. In addition, the mean number of viral copies/mL went significantly up (3. Use of cyclophosphamide-containing preparative regimen was not associated with an increased cumulative incidence of HC (4%). However, cyclophosphamide was primarily used in RIC in combination to low dose total body irradiation, fludarabine and Campath.
In addition, use of bone marrow versus peripheral blood had no influence on development of HC (incidence of 12% versus 8%, respectively, p=0.4). Similarly, no significant impact was found for age, diagnosis, disease status (remission versus active disease; incidence of 14% versus 9.4%, respectively), use of fludarabine-based conditioning (incidence of 12.8% (with fludarabine) versus 8% (without it), p=0.6), platelet or neutrophil engraftment, or a diagnosis of grade II-IV acute GVHD (HR 1.3, 95% CI, 0.5-3.5 p=0.6), considered as a time dependent variable ( Table 2 ). Post HSCT cytomegalovirus (CMV) reactivation occurred in 48% (n=100) of the patients during the first 4 months. There was no correlation between CMV antigenemia and development of HC (incidence of 13% versus 11% for antigenemia positive and negative patients, respectively).
Correlation of urinary cytology and BK PCR
Urine cytology data was available in 208 patients prior to HSCT. Nineteen (9%) were deemed to have changes compatible with polyoma virus infection. HC rates among cytology positive and negative patients were 16% (3 of 19) and 12% (22 of 189), respectively. Double negative samples (PCR and cytology) had a cystitis rate of 9% (9 of 103), while double positive patients had a HC rate of 22% (2 of 9 patients). Cytology negative but PCR positive samples were associated with cystitis in 15% of the cases (13 of 86), while cytology positive but PCR negative cases were linked to HC in 10% (1 of 10 cases). Ultimately, 22 of 25 patients (88%) that had HC had no polyoma-induced cytologic changes pre transplant, while 10 of 25 (40%) had no evidence of infection by PCR. At the time of diagnosis of HC, 10 of 13 patients in which the information was available had cytological changes suggestive of BK infection, usually associated with viruria greater than x 10 7 copies/mL. 
Hospital stay
Multivariate analysis
We performed stratified and multivariate analysis to adjust for the factors shown to be significant on univariate analysis (Table 3 ). Stratified analysis showed that the impact of donor type and PCR positivity pre transplant were significant in patients who received an ablative regimen, but not in those patients that received RIC. We adjusted for this interaction by considering the impact of donor type and PCR positivity pre transplant only in patients who received an ablative conditioning, allowing for RIC as a reference group. This classification showed that the incidence of HC was lowest among recipients of RIC conditioning and highest (58%) among recipients of ablative regimens, haploidentical and cord blood transplants, and those that had a positive PCR pre transplant (58% versus 7% for the reference group, HR 13.6, 95% CI, 4.7-39 p<0.001; figure 2c and Table 3 ).
Discussion
Our study showed that polyoma viruria was not per se an independent risk factor for HC, contrary to our central hypothesis. However, viruria interacted with regimen intensity and donor type leading to a very high risk of hemorrhage after transplant. We identified a subgroup of patients that is very likely to develop HC: recipients of haploidentical or unrelated cord blood transplants conditioned with myeloablative regimens that had positive viruria at the time of admission for treatment.
This study recapitulates in a prospective fashion our previous (retrospective) analysis that showed unrelated transplants to be associated with more HC than matched related transplants. 21 In that study, however, we did not have BK virus information, and only ablative (radiation-based) conditioning was used. One cannot avoid the impression that there is a continuum of increasing HC rates going from related, unrelated bone marrow or peripheral blood transplants, to unrelated cord blood and haploidentical transplants. It is possible that this reflects poorer immune recovery intrinsic to the latter group.
Interestingly, it has been reported by others 9 that although BK viruria was detected in autologous and allogeneic transplant patients, only the allogeneic group developed HC.
Here, infection per se was not statistically significantly associated with cystitis, illustrating the complexity of problem. Contrary to what has been previously suggested and would be expected if the immune recovery deficit alone is at play, we did not see a correlation
of HC with development of GVHD, studied as a time-dependent variable. Although we did not have detailed data on steroid or other immunosuppressants use, the initial treatment is standardized in our institution.
Another observation is that HC occurred after engraftment of neutrophils in the majority of the patients (and in most cases after platelet engraftment). We speculate that the neutrophil 'requirement' illustrates the presence of an inflammatory component, possibly triggered by preparative regimen and BK virus presence.
Cyclophosphamide use, a common 'culprit' in this setting, did not contribute to HC here. This is likely explained by the association of this drug with RIC in our institution, further suggesting the issue of dose intensity contribution to the problem. Most of our HC cases were of late onset, less likely to be chemotherapy-related. Given this limitation, we don't know if our conclusions would extend to fully myeloablative, cyclophosphamidecontaining regimens. Use of such preparative regimens has previously been demonstrated to be a risk factor for cystitis (mostly of early onset), although not all investigators confirmed this association, while others did not see a difference in late onset HC incidence between RIC and ablative regimens. 11, 13, 15, 19, 20, 25 .
The association of BK viruria and HC has been investigated for many years, but we failed to document a correlation between viral load and HC (or severity of cystitis), as previously suggested. 11, 12, [16] [17] [18] The proportion of patients with HC was very similar in all quartiles of urinary viral load. Given the lack of a clear cut threshold, we opted for We somewhat arbitrarily grouped recipients of unrelated cord blood and haploidentical related transplants together. Biologically, however, the two subgroups are likely different in that cord blood donors lack immunity to BK virus, while haploidentical grafts are more often associated with poor immune reconstitution after HSCT. 24 A limitation of our study is that we did not measure BK viremia. Others have shown an association between plasma viral load and development of hemorrhagic cystitis 25 , and it is possible that measuring both viremia and viruria may be more informative than each separately. Another limitation is the lack of information on other viruses, such as adenovirus which can also lead to HC. However, since our cohort was comprised of adult patients only, the contribution of adenovirus infection is likely to be small, as opposed to what happens in the pediatric population. 3, 26 Other potential risk factors for HC studied here had no significant impact in this prospectively studied cohort. Age, platelet engraftment, bone marrow versus peripheral blood grafts, BK virus PCR 30 days after transplant, and development of acute GVHD
were not independently associated with HC. 7, 19, 21 We believe these findings reinforce the interaction between BK virus, preparative regimen and donor type. The identification of this high-risk subgroup may provide a target for interventions designed to improve polyoma virus immune response post HSCT, and for avoidance of drugs that may increase HC incidence (such as cyclophosphamide). Our GVHD findings are somewhat limited, however, since we did not take into account intensity and duration of immunosuppressive treatment used to manage GVHD, nor the results of GVHD treatment, and should be interpreted with that in mind.
The morbidity of this complication should not be underestimated, as well as the logistic and financial implications of prolonged admissions and HC-mandated urologic interventions. Future insights in immune reconstitution after HSCT from donors other than HLA identical siblings are expected to shed light into this complex syndrome, and hopefully allow us to minimize the consequences of this complication of hematopoietic transplants.
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